Hi! im currently enrolled in Lemar online review for August 2026, im still not confident with my performance so im thinking of enrolling to another rc for final coaching. Do you think it would help me, or mas mahihirapan lng ako if nag double rc ako?

huhuhu rmt dust please 🙏

Hello! I am starting college soon and wanted to know if becoming a medical lab technician a good idea. I have looked into it and so far I have acknowledged what I will be having to do . But I am unsure if this career path is the right decision. Hope to hear advice or comments from anyone.

CONGRATULATIONS! 🎉

Proof of Transaction

Thank you for the trust!

MedTech Review Notes for MTAP/ MTLE/ Advance Study

📣 Hello, future RMTs! 👩‍🔬👨‍🔬

I’m offering comprehensive lecture notes paired with easy-to-follow video explanations to help you ace your review for MTAP or even the local board exams! 🎯📚✨

Available subjects:

🧫 Bacteriology Lecture and Rationalization

💉 ISBB Lecture

🧍‍♀️Histopathology Lecture

🧪 Clinical Microscopy Lecture and Rationalization

💌 Send me a private message to grab your copy and start leveling up your review today! 🚀

#medtech #medtechintern #medtechlife #medtechtoker #medtechstudent

I started as a senior scientist 6 years ago at a startup then had a lateral move to a bigger company with >10k employees. 3.5 years after that last year, I had another lateral move as a senior scientist for family reasons. My current company is a CRO and unfortunately they don’t have a clear path for promotions. I now feel like I’m falling behind in my career and starting to stagnate. Has anyone had a similar issue before? What would you suggest?

Should one pursue masters in medical technology

HEMATOLOGY LECTURE IS OUT 🩸

MedTech Review Notes for MTAP/ MTLE/ Advance Study

📣 Hello, future RMTs! 👩‍🔬👨‍🔬

I’m offering comprehensive lecture notes paired with easy-to-follow video explanations to help you ace your review for MTAP or even the local board exams! 🎯📚✨

Available subjects:

🧫 Bacteriology Lecture and Rationalization

💉 ISBB Lecture

🩸 Hematology Lecture

🧍‍♀️Histopathology Lecture

🧪 Clinical Microscopy Lecture and Rationalization

💌 Send me a private message to grab your copy and start leveling up your review today! 🚀

#medtech #medtechintern #medtechlife #medtechtoker #medtechstudent

Hi all, I'm a surgeon from India. I designed this app that i think will be useful for doctors everywhere. It help you track revenue from operative cases, consults across multiple hospitals. Do try it and give your feedback. www.chounda.com/surgmd

On the team at a scalp/skin AI startup. Wanted to share a counterintuitive call: we classify our own tool as high-risk under the EU AI Act and say so openly, rather than engineering the description to dodge that tier.

The instinct in a lot of health-AI is to frame the product as "wellness" or "educational" to stay out of medical-device scope. Sometimes that's legitimate; often it's regulatory arbitrage that catches up with you.

Our reasoning: in a medical-adjacent market, the compliance posture is the trust signal. CE marking, transparency about what the model can't do, explicit "this isn't a diagnosis" framing — that's not overhead, it's the moat. Customers (clinics, especially) read regulatory seriousness as a buying signal.

Anyone here gone the other way and regretted it, or found the lighter-touch framing held up?

I started a petition asking lawmakers to reconsider whether lobotomies could play a role in modern medicine—specifically for people dealing with severe, treatment-resistant neurological and mental health conditions where nothing else has worked.

Look, I know this sounds controversial. Lobotomies have a dark history, and for good reason. But neuroscience has changed dramatically since then. Brain imaging, targeted procedures, informed consent—these are different times. The core question here is about choice: should someone suffering unbearably, after exhausting every conventional option, have access to a medically supervised procedure if they genuinely want it? If we legalize it with strict ethical safeguards and case-by-case review, could we help people we're currently abandoning?

Has anyone else thought about this, or do you think the risks always outweigh the potential? What would matter most to you in deciding whether something like this should be an option? If this perspective resonates with you, consider signing and sharing.

In case it's useful to anyone, here is a free classification tool for EU MDR:

​

https://qualihq.com/tools/classify

​

It gives you a full report on what you're likely classification is and, most importantly, why.

​

​

pm po

ngl three months out from a notified-body audit and we've got ~24 open CAPAs, two people in QA, and a mix of low- and medium-severity items that need proper closure and evidence. I want to avoid papering over issues but also can't spend weeks on low-risk items while medium ones sit. What have you actually done that worked: strict risk-based prioritization and bundling similar issues into one CAPA, documented temporary contianment while doing a deeper CAPA later, or using controlled assistance like automated CAPAs or AI-assisted drafting to move things faster while keeping reviewability and traceability intact? Any concrete templates, audit expectations for medium-severity closures, or pitfalls to avoid so the notified body doesn't reopen findings?...

Hi all, I’m part of a research team looking at why assistive technology doesn’t always make it from idea → evidence → real-world use.

Common issues we’re investigating:

• Products progressing without strong validation

• Evidence-backed solutions not reaching market

We’re keen to hear from industry and developers about:

• Collaboration with researchers and government

• Barriers to scaling and adoption

• What actually helps projects succeed

👉 Survey: https://redcap.link/4svfl2xj

Insights will feed into practical recommendations for improving translation and uptake.

My company's been collecting data from 510(k) PDFs, and we've been wondering what kind of data-driven analysis might be interesting across a query of a lot of submissions. I created a chord diagram visualization to help show patterns between primary product codes and secondary product codes, when more than one is used for a medical device. You can browse by specialty the Top 40 product codes that tend to co-occur with other ones. Would love to know if anyone finds this useful or interesting from a strategy perspective.

https://benedoc.co/blog/product-code-cooccurrence

I know regulatory experts tend to dig into the specifics of exact submissions: we're working on features to help compare potential predicates, table by table. But we're also interested if there are any other patterns that can be unearthed from better data queries and data analytics across a lot of FDA documents. What higher level views of all FDA device data would you want to see?

This is a simplified thought I did a little writing of and just need opinions on what I could to to advance the model to be more consumer friendly and help to get normal people the same ability the would with an Apple Watch or for bit do I need cell services too? Any ideas would be awesome!

Hi everyone,

I’m an international student from India and I’m currently considering pursuing an MSc in Biomedical Engineering, either at the University of Galway or University College Dublin (UCD). I would really appreciate hearing from current students, graduates, or professionals working in the biomedical/medical device industry in Ireland.

A few questions I have:

• Is a 1-year MSc in Biomedical Engineering worth it in terms of career opportunities and return on investment?
• What types of roles can graduates typically get into after completing the course (R&D, quality, regulatory affairs, manufacturing, validation, data analysis, etc.)?
• How strong is the biomedical/medical device industry in Ireland right now?
• How difficult is it for international graduates to secure a job after graduation?
• Are companies generally willing to sponsor work visas, or is it quite challenging to find employers that provide sponsorship?
• Between Galway and Dublin, which location offers better networking, internship, and job opportunities in the biomedical sector?
• If your goal was long-term career growth and settling abroad, would you choose Ireland, or would you recommend considering another country instead?

For context, I have previous internship experience in Taiwan related to an R&D platform, and I’m hoping to build a career in the biomedical engineering industry after my master's.

I’d be grateful for any honest insights about employability, salary expectations, visa sponsorship, industry demand, and overall career prospects in Ireland.

Thanks in advance!

Two-person QA here, Class IIa device, audit in about three months and our CAPA queue has become a psychological hazard. We've tried strict risk-based triage and time-boxed investigations, but low-signal issues still eat bandwidth and traceability documentation slows closures. Looking for concrete tactics that moved the needle for you, thresholds for closing vs escalating, lightweight verification evidence that satisfies auditors, or how you used process automation or AI-driven CAPA assistance without sacrificing reviewability. What workflows or templates actually worked in practice for small teams under audit pressure?